REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model

Glasgow, UK — Scientists from REPROCELL Europe, working in collaboration with researchers at Durham University, have successfully developed a full-thickness human skin model using fibroblasts derived from induced pluripotent stem cells (iPSCs). The breakthrough, published in Cells (14(14):1044, 2025), demonstrates a novel approach to producing consistent, high-quality human skin constructs for research and therapeutic applications.

Current skin models often rely on primary human dermal fibroblasts, which can be difficult to source and vary in quality between donors. In this new study, the joint REPROCELL–Durham University team generated iPSC-derived fibroblasts (iDFs) that closely mimic the characteristics of primary cells—offering a reliable and scalable alternative.

Key findings from the research include:

• Comparable cell performance: iDFs showed similar growth, marker expression, and extracellular matrix production to primary human dermal fibroblasts.
• 3D dermal layer formation: iDFs successfully infiltrated porous scaffolds, depositing collagen I and fibronectin to form a robust dermal equivalent.
• Support for epidermal development: When layered with primary keratinocytes, the iDF-based dermal equivalent supported the formation of a fully stratified, differentiated epidermis with correct localization of barrier and structural proteins.

Significance for research and medicine

This work highlights the potential of iPSC-derived fibroblasts to provide a consistent, ethically sourced supply of human dermal cells for use in skin models. Such models play a vital role in drug discovery, disease research, and regenerative medicine, offering scientists a reliable and scalable platform for testing and development.

The study also opens the door to further innovation. By incorporating additional iPSC-derived cell types—such as keratinocytes, melanocytes, and immune cells—the platform could be adapted for personalized disease modelling, advanced safety testing, and therapeutic development.

Find the whole paper here.